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ABSTRACT (Maximum 200 Words)
Receptor Tyrosine Kinases (RTKs) have been identified as potential targets for both breast cancer prognosis and therapy.
We proposed use of tissue microarrays to evaluate the prognostic value of RTKs with emphasis on the phosphorylation status of these receptors.
Analysis of a series of phospho-receptor antibodies on large cohorts on tissue microarrays should reveal which RTKs are most likely to be of prognostic and therapeutic value.
As of this progress report, we have completed construction of the tissue microarrays and completed collection of the clinical data.
We have also completed and submitted a pilot study of RTKs using conventional analysis of this array.
In the proposal we show automated analysis of the arrays has potential to reveal relationships that are undetectable by conventional methods.
We have now completed our efforts in construction of the device capable of high through-put automated array analysis.
We have completed studies using this technology (called AQUA, for automated quantitative analysis)on a number of RTKs.
Although we were unable to successfully use phosphor-Ab, the quantitative assess of the RTKs themselves provided novel information with respect Biologically specific therapies represent a great new hope for combating cancer. Perhaps the best example of this is Herceptin, a specific drug for a subset of patients with HER2 positive breast cancer. Unfortunately, the pathway from initial discovery to clinical usage is long and slow, taking over 10 years for HER2 (a member of the receptor tyrosine kinases (RTK) family. In this study we proposed a potential method for rapid evaluation of other RTKs as bio-specific therapies based on prediction of outcome. We proposed that phospho-specific antibodies to RTK would provide highly specific prognostic markers for outcome and predictive markers for response to anti-receptor type therapies. Our objective was to produce specific phospho-RTK antibodies and then to evaluate them using breast cancer tissue microarrays. Breast cancer tissue microarrays are a method of placing 0.6 mm diameter samples of breast cancers from hundreds of patients on a single slide. Using this method we proposed high throughput screening for potential prognostic antibodies at the earliest stages of antibody development.
Body:
The main difficulty in finding these potential new RTK targets is that there are many potential candidates and it is difficult and expensive to evaluate a large number of antibodies on large breast cancer cohorts using conventional methods. The novelty or "idea" of this proposal is the use of a newly described, high throughput mechanism for evaluation of antibodies. Thus instead of producing candidate antibodies and screening using the conventional approach (which can take many years), we propose reversal of this process, screening for candidates using the outcome testing, then only proceeding with development of antibodies that have already been validated on large populations of breast cancer patients. We originally proposed the following specific aims:
1. Construction of a series of candidate phospho-RTK antigens and immunization into mice. 2. Evaluation of mouse test bleeds using 250 case, 3-fold redundant, breast cancer cohort tissue microarrays. 3. Selection of promising sera and production of monoclonal antibodies followed by confirmatory testing on tissue microarrays.
Our original Statement of Work was as follows: This progress report describes work completed during the three year duration of this grant.
In evaluation of the optimal RTKs for antibody preparation we consulted many sources. We found that many biotech antibody companies had already embarked on production of phosphospecific and other RTK antibody production. Rather that try to duplicate their efforts, we decided to begin by purchasing some of the 100's of RTK antibodies that are now commercially available.
Prior to testing any antibodies, arrays needed to be constructed and cohort data collected. That process was completed during the first year. We now have constructed 3 master array blocks for analysis. They include YTMAIO, including 350 node positive cases, YTMA 12, including 350 node negative cases, and YTMA 23, including a total of 250 cases representing a subset of the previous cohorts (125 node negative and 125 node positive) that have ample tissue available for analysis of multiple antibodies. During the analysis of YTMA 10 and 12 we found some slide to slide variability, such that is would be advantageous to mix the node positives (YTMAIO) with the node negative (YTMA 12) . This was done and produced as YTMA-49. This array was used extensively for studies on the RTKs.
After completion of construction of the arrays, we began a two-fold approach to analysis. As a proof of concept, we selected 5 RTKs (HER2, MET, EGFR, FGFR, and IGFR) as test cases. Dr. Tolgay Ocal, a pathologist recruited to this effort, analyzed expression of these markers using YTMA 12. He found that only Met was predictive of outcome in the node-negative population but that we were able to group MET and FGFR in a single group that was unrelated to HER2 and EGFR which comprised a second, unrelated group. Furthermore, he found that the localization of the epitope on Met was critical for prognostication of outcome. Specifically, the C-terminal antibody (3D4) was significantly associated with poor outcome, but a second antibody recognizing the extra-cellular domain of the Met beta chain was not at all associated with outcome. This was confirmed in a second effort using the same array looking at Met, matriptase, HAI I and HGF led by Julie Kang. Both of these efforts have now been published and both papers are included in the appendix.
Although we were pleased with these results, the original grant discussed analysis of arrays using a more quantitative method than the ordinal subjective scale used in this study. Toward that aim, other investigators in the lab have finalized a method for automated quantitative analysis of tissue microarrays. This work will be extremely valuable in optimizing the high throughput analysis of arrays in the future. Although the automated analysis development work was not funded by this grant, it impacts the grant dramatically. The paper that describes the new automated analysis system (AQUA) was published in Nov 2002 in Nature Medicine. That technology has now been used on a series of RTKs.
The automated analysis system was designed on the Applied Precision Deltavision platform, but that platform is not well suited to the task and the system at our institution is very heavily used allowing only limited time for our applications. Approval of a rebudgeting request allowed the purchase of a new dedicated 2 nd generation automated tissue microarray analysis device. This device (called Professor Marvel, in honor of its location behind the curtain) is functioning well and the basis for all automated analysis experiments.
The next step was the evaluation of multiple phospho-specific antibodies. Although we originally proposed making our own phospho-specific antibodies, since that proposal, many have become commercially available. Thus we have purchased a number of antibodies to the tyrosines proposed in the original grant. Over the last 2 years, we have focused on the phosphotyrosines of Met, EGFR, and HER2. The antibodies were purchased from Cell Signaling Technologies (CST), Upstate Biochemical and Biosource. We collected data on all of the phospho-tyrosines on EGFR and all of the phosphor tyrosines of Met using the 250 case TMA. These antibodies have shown some unexpected subcellular localizations (specifically many are nuclear). This has led to questions regarding antibody cross reactivity or non-specificity.
This led to validation studies of three Phospho-Met antibodies from BioSource. Although these are not monoclonals, they are made from three phospho-peptides (Y1003, Y1235, and Y1349), and then affinity purified. Others and we have shown these antibodies work on western blots by showing increased phosphorylation after stimulation with HGF, the Met ligand. However, the patterns on test arrays were variable from case to case and the localization was not similar to that seen with some Met antibodies. Toward validation of these antibodies, first we used incubation with phosphatases to determine if the antigens are destroyed. We found that Calf Intestinal Alkaline Phosphatase was sufficient to abolish essentially all activity of the phospho-Met antibodies. Next we tested the specificity of each of the three phospho-met antibodies by using purified phospho-peptides to assess competitive inhibition of the interactions on tissue arrays. Figure 1 shows that the Y1349 antibody is somewhat diminished (row 3) or barely at all diminished (row 1) by the phospho-Y1349 peptide, but it is similarly competed by the phospho-Y1003 and Y1235 peptides. We conclude that even though there is specificity on a western blot, on fixed tissue there is significant cross-reactivity that will prevent future use of these antibodies in this project.
Although were are still concerned about the heterogeneity of phosphorylation, we plan to proceed to test further phospho-specific monoclonal antibodies, beginning with the Cell Signaling Technologies phospho-EGFR antibodies. Over the last year Julie Kang and Matt Neopolitano tested phosphor-EGFR and phosphor-met antibodies on YTMA 23 (the 250 case cohort). These studies showed disappointing results in multiple ways. Initially data analysis showed that all markers analyzed showed no relationship to outcome. While Tyr 845 of EGFR trended toward significance, the data was disappointing. Further analysis suggested two main problems that lead to abandonment of this strategy. Firstly, we found heterogeneity it the phosphorspecific antibodies that was not seen with other antibodies, raising the possibility that variation in phosphatase activity prior to fixation may represent a fatal flaw in the cohort. We had no way to control for this variable since the tissue was collected from archival material from many years ago. The second major problem was a incompatibility in the amplification scheme. We found that the membrane compartmentalization marker that was used (ConA) caused increased background, most likely due to interaction with the dextran backbone in the EnvisionTM kit used for measuring the target in the AQUA system. Given this series of problems and some changes in personnel, we decided to focus more on the HER family molecules themselves in preparation for analysis to look at dimerization and or colocalization with downstream binding partners. This work was done by a new MD-PhD student that entered the lab, Jena Giltnane. She has found that different EGF antibodies show highly variable patterns and levels of expression dependent on the epitope (see figure 2) . The Dako antibody showed borderline significance in prediction of outcome, while the CST antibody showed no relationship to outcome. The data in preliminary and will be repeated to increase the spot redundancy. Jena has also done a preliminary analysis comparing expression levels between the other HER family molecules. This is the subject of a new Army Idea grant submitted last June. Analysis of RTKs shows MET is predictive of outcome in a node-negative population and it identifies a series of patients unique from that identified by over-expression of HER2 or EGFR but related to those that over-express FGFR.
Conclusions:
Tissue microarrays are a valuable tool for analysis of protein and phospho-protein expression.
Completion of our automated analysis system will allow high throughput analysis of these arrays. We have further developed and system for quantitative analysis of these arrays. We have now switched over to exclusively using this AQUA technology.
The significance of these developments is that we are now well positioned to find a series of valuable prognostic markers. Aithough phosphor-specific antibodies were a disappointment due to uncontrollable issues in the fixation process, the antibodies to the RTKs themselves have been measured in a quantitative manner and we have show that different regions of the molecule show different staining patterns and different associations with outcome. These markers and their downstream binding partners are likely to be valuable for prognostication and prediction as the number of RTK specific drugs increases.
References: See original proposal.
Shundreds of tissue sections from different tumors arrayed on a cent tags to separate tumors from stroma and to define subcelSsingle glass slide-facilitates rapid evaluation of large-scale lular compartments. The distribution of a target antigen is then i outcome studies. Realization of this potential depends on the quantitatively assessed according to its co-localization with ability to rapidly and precisely quantify the protein expression these tags. As subcellular compartments (for example, mem-.i within each tissue spot. We have developed a set of algorithms brane, cytoplasm, nuclei and so forth) of different tissues and 3 that allow the rapid, automated, continuous and quantitative tumors vary widely in size and shape, traditional methods of i analysis of tissue microarrays, including the separation of defining compartments based on morphometric criteria (that tumor from stromal elements and the sub-cellular localization is, feature extraction) perform poorly on a large-scale basis. of signals. Validation studies using estrogen receptor in breast
Rather than counting target-containing features, PLACE delincarcinoma show that automated analysis matches or exceeds eates target expression as the suni of its intensity divided by the " the results of conventional pathologist-based scoring, total size of the assayed compartment.
CAutomated analysis and sub-cellular localization of betaAs the thickness of tissue sections makes it difficult to dis-2 catenin in colon cancer identifies two novel, prognostically sig-criminate between overlapping subcellular compartments, we nificant tumor subsets, not detected by traditional have also developed a novel, rapid exponential subtraction al-C pathologist-based scoring. Development of automated analy-gorithm (RESA), which subtracts an out-of-focus image, col-
sis technology empowers tissue microarrays for use in lected slightly below the bottom of the tissue, from an in-focus . discovery-type experiments (more typical of cDNA microar-image, based on pixel intensity, signal-to-noise ratio, and the a.
rays), with the added advantage of inclusion of long-term de-expected compartment size. This algorithm dramatically im-0 mographic and patient outcome information, proves the assignment of pixels to a particular subcellular com-E partment ( Fig. 1) . For a more complete discussion of the image Despite the promise of automated analysis of histological secmanipulations performed in this protocol, see Supplementary 4 tions, it has failed to replace traditional, pathologist-based Methods or http://www.yalepath.org/dept/research/YC-C4 evaluation, even in the simplest of conditions such as the CTMA/tisarray.htm. o analysis of hnmunohistochemical stains. Whereas the automated analysis of isolated cells in fluids or smears (for example, Validation of AQUA algorithms * fluorescent cell sorting and laser scan cytometry) is now rou-Our initial validation of this technology compared its accuracy, tine', the analysis of tissue sections is hampered by the fact that intra-observer variability, and predictive power to traditional tumor tissue is a complex mixture of overlapping malignant pathologist-based analysis. We stained a tissue microarray detumor cells, benign host-derived cells and extracellular mater-rived from 340 node-positive breast-carcinoma patients for the ial. Several methods (including confocal and convolution/de-presence of estrogen receptor (ER)-the oldest and most comconvolution microscopy) can determine the subcellular mon prognostic marker for breast cancer. First we analyzed the localization of target antigens, but only through computation-ability of automated analysis to match results from a patholoally intensive techniques, requiring the acquisition of multiple gist-based evaluation and found a high degree of correlation (R high-power, serial images 2 . Methods designed for tissue mi-= 0.884, Fig 2a) . Next, we compared the variability of a patholcroarrays perform only limited subcellular localization using ogist-based and automated analysis of two separate histospots morphometry and usually require significant manual interface derived from the same tumor ( Fig. 2b and c0 . This comparison (for example, drawing polygons around tumor cells)" 4 . In gen-shows that automated analysis has slightly better reproducibileral, pathologist-based analysis remains the current standard ity (R = 0.824 versus R = 0.732). for the immunohistochemical studies.
Although automated analysis compares favorably with Tissue microarrays provide a high-throughput method of an-pathologist-based interpretation of microarrays, the true critealyzing the prognostic benefit of a myriad of potential targets rion standard is outcome prediction. Estrogen receptor expreson large cohorts of patient samples", but are limited by the sion is known to significantly improve outcome, because it is pathologist's ability to reproducibly score on a continuous associated with less aggressive tumors that are more responsive scale, discriminate between subtle low-level staining differ-to anti-estrogenics (for example, Tamoxifen). We compared ences, and accurately score expression within subcellular corn-the survival of patients with tumors with high (top 25%) versus partments. We have developed a set of algorithms that we call low (bottom 25%) ER expression as assessed by both automated AQUA (Automated Quantitative Analysis) that allow the rapid, and pathologist-based scoring (Fig. 2d) carcinomas were stained and scored by a patholoist using a traditional H-score algorithm. Note that despite good correlation (R = 0.732), there is significant discontinuity in the scoring pattern "., with numerous scores clustered around the high and low-end of the scale. b, Automated analysis . was performed using the RESA and PLACE algorithms and compared to the pathologist's score with n", a high degree of correlation (R = 0.884). r, A comparison of two automated reads of two different microarrays derived from the same cohort also shows excellent correlation (R = 0.824). d, To deter-
mine the potential of each system to predict outcome, survival curves were plotted for the top and bottom 25% ER expressers using each scoring system: Red, automated; blue, pathologist-based; -3 dotted, top 25%; solid, bottom 25%. Both systems provided a statistically significant survival difference (P = 0.0003 and P = 0.0020, automated and pathologist-based, respectively). Fig. 3 Increasing levels of nuclear P-catenin associate with an increasingly poor prognosis. The d relative amount of nuclear-associated 0-catenin was analyzed in our cohort of 310 colon carcino-A mas. a, Analysis of nuclear 13-catenin levels in a pathologist-based analysis using a 4-point scale 
.C
ER staining results in Fig. 2 . Note the preponderance of scores of adhesion complexes, hi contrast, nuclear-associated fI-C" at O, 100, 200 and 300. Furthermore, on average, over half of catenin activates several genes important in cell proliferation 2 tthe cases were assigned to one extreme or the other (39% at 0 and invasion" 2 . In development, translocation of P-catenin to 0 and 12% at 300). Thus 51% of the cases could not be effectively the nucleus results frons wnt-mediated cell signaling" 3 . c ranked. In contrast, the range of scores from the automated However, spurious activation of this pathway is often seen in * analysis is continuous from 0 to 1000. We hypothesize that the tumors through mutation of P-catenin or other proteins intwo key advantages of automated assessment, continuity of volved in its activation and/or degradation'. Studies on the a.
scoring and accurate subcellular localization, will allow tumor prognostic value of 13-catenin have been mixed"•"'. f classification beyond that attainable by current methods. The complex biology and uncertain prognostic value of i.-
Scatenin
made it a suitable candidate for assessing the value of 2
Compartmental analysis of beta-catenin expression quantitative subcellular localization. We studied a cohort of g To demonstrate this potential, we analyzed P-catenin expres-310 colon cancers, using both pathologist-based and auto-8C.4 sion in colon cancer. f-catenin is an ideal candidate in that it mated systems for scoring overall, nuclear and membrane-assoo exhibits complex subcellular localization and manifests onco-ciated levels of Prcatenin expression. Manual analysis used a genic properties upon localization to the nucleus" 3 . Numerous traditional 4-point nominal scale (0 through 3+), whereas auto-, studies have shown that f-catenin plays a dual role in both mated analysis used a continuous 1,000-point scale. In a previcell-cell adhesion and cell proliferation, depending on its loca-ous study using a similar cohort, we were unable to find tion". Membrane-associated 1-catenii stabilizes cadherins-prognostic value in assessing nuclear f-catenin levels' 8 . These mediated adhesion by facilitating the cytoskeletal attachment data were confirmed in our present study when comparing tu- FIg. 4 Unlike analyses of overall 0-catenin expression, automated, analysis, demonstrates that tumors with higher relative nuclear expressubcellular localization of IS-catenin can predict outcome in colon carcision do worse than those with higher relative membrane expression (P = noma. a, Overall 1i-catenin levels in a cohort of 310 colon cancers were 0.0264, top versus bottom 25% of cases, RR = 1.718, 95% Cl = evaluated by a pathologist using a 4-point scale (0-3+). Survival analysis 1.059-2.787). Note that the nuclear/membrane ratio identifies a large of tumors with the lowest (0) versus highest (3+) overall P-catenin exsubset (25%) of tumors with poor prognosis, the majority of which are pression was not significant (P = 0.9425). b, Similarly, automated analynot identified by analyzing individual subcellular compartments. sis of overall 0-catenin levels, comparing cases in the top and bottom Indeed, comparison of tumors with high nuclear/membrane ratios (top 25%, failed to detect a survival difference (P -0.4551). c, In contrast, 25%) versus those with high nuclear 0-catenin (top 25%) shows that the ratio of nuclear to membrane P-catenin, as assessed by automated there is only 47% overlap. inors expressing the highest levels of nuclear l1-catenin (3+, dependent prognostic significance because it is highly correlated representing 19% of the cases) versus the rest (Fig 3a) (P = with nodal metastases (see Supplementary Methods online). 0.2354). We hypothesized that with the benefit of automated, The methods presented here are highly adaptable to a numcontinuous assessment, these 3+ cases could be subdivided into ber of tumor types and target markers. In most cases, compartcases expressing very high versus high levels. We began by an-nrient-specific tags are identical regardless of tumor type (DAPI alyzing the top 25% of tumors expressing nuclear P-catenin, as for nuclei, cadherins/catenin complexes for membranes). assessed by automated analysis. This group shows a trend to-Because the methods do not use heuristic models that require ward poorer survival (Fig 3h) (P = 0.0760). When we subset the recognition of compartments according to size, shape or textumors to assess the top 10% expressers, there is a statistically ture, they are fully adaptable to tumors with overlapping or significant survival difference ( Fig. 3c ) (P = 0.0332, relative risk pleomorphic cells and/or nuclei. Furthermore, the algorithms = 1.740). Further fractionation of the data reveals that the top can be easily expanded to cover novel compartments or even i 6.7% (15" percentile) exhibit even poorer survival with a 'virtual' compartments (for example, mitochondria, lysohigher statistical significance ( Fig. 3d ) (P = 0.0038, relative risk somes, cortical actin ring) or tumor types (for example, = 2.41S). This analysis demonstrates the power of continuous mesothelioma), as long as tags can be identified for the -automated assessment to define subsets of tumors not seen prospective compartments/cell types. Iln addition to ER and using standard pathologist-based assessment. Unlike Il-catenin, P-catenin, we have used these techniques to successfully aiasubdividing ER into smaller and smaller subsets does not signif-lyze dozens of nmarkers, including growth factor receptors, liSicantly alter its prognostic ability, suggesting that ER may be a tracellular signaling molecules, and proliferation markers, Struly continuous marker where no subpopulations exist, using both conventional and phospho-specific antibodies (see Supplementary Methods online). Analysis of these targets re-I Tumor classification using the AQUA algorithms quires only a standard antibody titration. We then attempted a tumor classification based on comparative
N E W T E C H N
We have found that most antigens benefit from subcellular o. subcellular localization. As the translocation of f3-catenin from localization. Localization can be simple, such as determining "= the membrane to the nucleus is thought to correlate with tran-the amount of the proliferation marker KI-67 in tumor nuclei, CL scriptional activation, we analyzed the ratio of nuclear to mem-or more complex as in the case of P3-catenin. Localization of in-2 brane-localized 13-catenin. By its nature, this type of analysis is tracellular signaling molecules (for example, STATs) may be O essentially impossible without continuous scoring. A crude mea-vital in assessing their potential as prognostic markers. In addi-0, C surement of overall 3-catenin levels using either a pathologist-tion, recent studies have shown that membrane-bound growth 0 based or an automated system fails to demonstrate a significant factor receptors (for example, epidermal growth factors, EGFR : difference hi survival between the highest and lowest expressing and ERB-B4, and fibroblast growth factor) can translocate to a.
tumors (Fig. 4 , a and b, P = 0.9425 and P = 0.4551, respectively), the nucleus and may act as transcriptional regulators19.
SIn contrast, when we ratio the level of nuclear/membrane 13-Subcellular localization of such markers may be critical to their Scatenin, we find that tumors with a high ratio have a worse out-use as prognostic markers in cancer.
come than tumors with a low ratio (RR = 1.718, P = 0.0284). Note Depending upon the array size, and the complexity of the 4 that this method defines a relatively large subset (25%) of tumors compartmentalization, analyses using our current device take SN with poor prognosis, the majority of which are not identified by from 1-3 hours for image acquisition, and 1-2 hours for analyo analyzing individual subcellular compartments. Indeed, a corn-sis. In our laboratory, the average pathologist-based analysis parison of the tumors with the highest nuclear/membrane ratio rate is 50-100 spots per hour and usually is performed in sev-, (top 25%) versus the highest overall nuclear levels of P-catenin eral sessions. To increase precision, two or more pathologists (top 25%) shows that there is only 47% overlap between the two read the same array independently and then together to resubsets. Multivariate analysis of nuclear/membrane f-catenin rasolve discrepancies. Aside from being more accurate and more tios shows independent prognostic significance when analyzed robust, automated analysis cars be performed continuously and with depth of invasion, nodal status, tumor grade and patient age results tabulated immediately. We estimate that a fully inte-(RR = 1.865, 95% Cl = 1.068-3.259, P = 0.0285). In contrast, mul-grated tissue microarray reader could be 30 to 50 times faster tivariate analysis of total nuclear k-catenin levels fails to show in-than pathologist-based scoring.
Methods catenin) as well as target signals (ER and fi-catenin). Regions of Tissue microarray design and processing. Paraffin-embedded tumor were identified using a mask derived from a ubiquiformalln-fixed specimens from 345 cases of node-positive breast tously expressed epithelial-specific antigen (either cytokeratin carcinoma (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) and 310 cases of colon carcinoma or x-catenin). Images were analyzed using RESA and PLACE al-(1971-1982) were obtained, as available, from the archives of gorithms as detailed in the Supplementary Methods online. the Yale University Department of Pathology. Microarray slides Results were expressed as the intensity of the target signal in were prepared, processed and stained as described in the each compartment divided by the compartment. For ER, only Supplementary Methods online. For manual analysis, slides were nuclear-localized signal was used; for frcatenin total signal, visualized with diaminobenzidine (DAB). For automated analythe ratios of nuclear-to-membrane signal and nuclear-to-total sis, slides were visualized with Cy-S tyramide.
signal were analyzed. Overall survival analysis was assessed using Kaplan-Meier analysis and the Mantel-Cox log-rank Image and data analysis. Monochromatic images of tissue score for assessing statistical significance. Relative risk was asmicroarray histospots were obtained using fluorescently lasessed using the univariate and multivariate Cox-proportional beled compartment specific tags (anti-cytokeratin, DAPI, ahazards model. 
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NEW TECHNOLOGY
Our data show that quantitative, continuous-scale, compart- 
Materials and methods
Tissue microarray design and processing. Paraffin-enmbedded, formalin-fixed specimens from 345 cases of node-positive breast carcinoma (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) and 310 cases of colon carcinoma (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) were obtained, as available, from the archives of the Yale University, Department of Pathology. Areas of invasive carcinoma, away from in situ lesions and normal epithelium, were identified and two 0.6-mm cores were taken from separate areas. Each core was arrayed into recipient blocks in a 1 mm-spaced grid covering approximately 1 square inch, and S-micron thick sections were cut and processed as previously described'.
Immunohistochemistry. In brief, pre-cut paraffin-coated tissue microarray slides were deparaffinized and antigen-retrieved by pressure-cooking 2 . Slides were preincubated with 0.3% bovine serum albumin in 0.1M tris-buffered saline (pH 8.0) (BSA/['BS) for 30 miin at room temperature. Slides were then incubated with primary antibodies diluted in BSA/TBS either for I h at room temperature or overnight at 4 *C. Slides were washed 3x 5 min with BSA/TBS containing 0.05% Tween-20. Corresponding secondary antibodies were applied for 1 h at room temperature in BSA/TBS. These included either antibodies directly conjugated to a filuorphore (Amersham, Piscataway, New Jersey and Molecular Probes, Eugene, Oregon), and/or conjugated to a horseradish peroxidase (HRP) decorated dextran-polymer backbone (Envision, DAKO, Carpinteria, California). DAPI was included with the secondary antibodies to visualize nuclei. Slides were again washed 3x S miin with BSAiTBS containing 0.05% Tween-20. For manual analysis, slides were then incubated with diaminobenzidine (DAB, DAKO). For automated analysis, slides were incubated with a fluorescent chromagen (Cy-S-tyramide, NEN Life Science Products, Boston, Massachusetts) which, like DAB, is activated by HRP and results in the deposition of numerous covalently associated Cy-S dyes immediately adjacent to the tiRP-conjugated secondary antibody. Cy-S (red) was used because its emission peak is well outside the green-orange spectrum of tissue autofluorescence. Slides for automated analysis were coverslipped with an antifade-containing mounting medium (Gelvatol with 0.6% n-propyl gallate). Manual examination of microarrays for ER and P-catenin levels has been previously described 3 .
Specifically, four sets of primaries and secondaries were used: Image acquisition. Images of mnicroarrays were obtained using a Deltavision platform and software (SoftWorx 2.5; Applied Precision, Issaquah, Washington), with an attached water-cooled Photometrics series 300 camera through a x10 Nikon Super-Fluor lens on a TE200 inverted fluorescent microscope with automated x, y, z stage movement. low power images of microarrays were stitched together using multiple (-1500) low-resolution images of the microarray (64 x 64 pixel) at approximately 7-micron resolution. Histospots were identified using signal from DAPI, cytokeratin, or ix-catenin tags. This signal was thresholded to create a binary image of the microarray. Histospots were identified using size criteria. Rows and columns of histospots were then identified, arid missing histospots filled in, allowing each histospot to be identified based on its row/column grid position. The coordinates of each histospot were then recorded. Subsequently, monochromatic, high-resolution (1024 x 1024 pixel, 0.S-micron resolution) images were obtained of each histospot, both in the plane of focus arid 8 microns below it, and recorded in an image stack as bitmaps. This depth, slightly below the bottom of the tissue, was determined to be optimal for S-micron histologic sections. A resolution of 0.S microns is suitable for distinguishing between large subcellular compartments such as the cell niembrane and nuclei. In theory, smaller compartments (for example, mitochondria, nucleoli) might require higher resolution. Images were obtained using a dynamic range of 0-1024, but saved and analyzed as 8-bit tiff images with a dynamic range of 0-2S5.
RESA/PLACE algorithmic analysis of Images. First, a tumor-specific mask is generated by thresholding the image of a marker that differentiates tumor from surrounding stroma and/or leukocytes. This creates a binary mask (each pixel is either 'on' or 'off'). In this study we used cytokeratin and a-catenin to create tumor masks. As formalin-fixed tissues caml exhibit autofluorescence, analysis may give multiple background peaks. The RESA/PLACE algorithms determine which of these peaks is predominant and sets a binary mask threshold at a slightly higher intensity level. This provides an adaptive (unique to each histospot) thresholding system that ensures that only the target signal from the tumor arid not the surrounding elements is analyzed. Thresholding levels were verified by spotchecking a few Images and then automated for the remaining images. This binary mask can be modified using standard image manipulations. In most cases this involves filling holes of a particular size (for example, less than 500 pixels, to fill in tumor nuclei that do not stain for either cytokeratin or rt-catenin) and removing extraneous single pixels. Once set, these image manipulations are performed automiatically oil all images. All subsequent image manipulations involve only image information from the masked area. Next, two images (one in-focus, one slightly deeper) are taken of the compartment-specific tags and the target marker. A percent-.. ............. .......................... °   .°  ° ...  ..... ............ ........... • ................... ° ...... ...............................  ...... I.......... ............. ................. ................... ........°....° .................. ......... age of the out-of-focus image is subtracted from the in-focus image, based on a pixel-by-pixel analysis of the two images. This percentage is determined according to the ratio of the highest/lowest intensity pixels in the in-focus image -representing the signal-tonoise ratio of the image. By using an exponential scale, this allows RESA to subtract low intensity pixels in images with a low signal-to-noise ratio less heavily than low intensity pixels from images with a high signal-to-noise ratio. The overall degree of subtraction is based on a user-defined percentage for each subcellular compartment. For most applications this is empirically set to 40% of the total signal, and remains constant for images from an entire microarray. RFSA thus eliminates all out-of-focus information. The algorithm has the added benefit of enhancing the interface between areas of higher intensity staining and adjacent areas of lower intensity staining, allowing more accurate assignment of pixels of adjacent compartments. In contrast to the compartmentspecific tags, the RESA subtraction of the target signal is uniform and not based on overall intensity of the image intensity. This ensures that the same amount of subtraction occurs with the target signal from all specimens. Finally, the PLACE algorithm assigns each pixel in the image to a specific subcellular compartment (Supplemental Figs. I and 2 ). Pixels that cannot be accurately assigned to a compartment to within a user-defined degree of confidence (usually 95%) are discarded. This is accomplished iteratively by determining the ratio of signal from two compartment-specific markers that minimizes the spillover of marker from one compartment into another. Pixels where the nuclear and membrane pixel intensities are too similar to be accurately assigned are negated (usually comprising <8% of the total pixels). A third compartment (the cytoplasm) can be defined by exclusion (non-membrane, non-nuclear). Once each pixel is assigned to a subcellular compartment (or excluded as described above), the signal in each location is added up. This data is saved and can subsequently be expressed either as a percentage of total signal or as the average signal intensity per compartment area. The score is expressed on a scale of 1 to 1000 as the total intensity detectable in a pixel ranges from 1-255 creating 3 significant figures. These algorithms are described in a recently submitted patent of this technology owned by Yale University. In this study, for ER, only nuclear-localized signal was used; for frcatenin total signal, the ratio of nuclear to membrane signal, and the ratio of nuclear to total signal was analyzed.Scores were adjusted according to amount of area covered by the subcellular compartments within the masked area Data analysis. Staining scores from the breast cancer histospots represent the averaged results from two independently scored histospots. Histospot containing <10% tumor, as assessed either subjectively (manual) or by mask area (automated), were excluded from further analysis. For the purposes of validation, we did not manually exclude any images of histospots exhibiting aberrant staining (for example, with normal epithelium or in situ carcinoma), although such manual assessment could be performed. Our previous studies have demonstrated that scores from the average of two histospots matches the score from an entire tissue section >95% of the time 4 . Subsequent studies revealed that analysis of a single histospot could provide significant statistical power to judge outcomes (data not shown), so that staining scores from the colon cancer array represent the result of only one histospot. Estrogen receptor expression showed continuous prognostic significance such that virtually any division between low and high expressers resulted in a significant survival difference; therefore, we chose the top and bottom 2 5 ' , percentiles as arbitrary divisions for high and low expression. Overall survival analysis was assessed using Kaplan-Meier analysis and the Mantel-Cox log-rank score for assessing statistical significance. Relative risk was assessed using the univariate and multivariate Cox-proportional hazards model (Tables 1-4) . Analyses were performed using Statview 5.0.1 (SAS Institute, Cary, North Carolina). Fig. 1 Subcellular localization of P-catenin in three sample colon carcinomas. The importance of subcellular localization in automated analysis is exemplified by three colon carcinomas. An image of the carcinomas stained for 0-catenin is shown of the left (grayscale), and the corresponding co-localization of that signal to subcellular compartments using RESA and PLACE is shown on the right (color). a, Automated analysis of a colon carcinoma with predominantly membrane-associated O-catenin shows co-localization of the signal to the membrane (red) with little signal in the cytoplasm (green) or nuclei (blue). b, Automated analysis of a carcinoma with predominantly nuclear-associated f3-catenin shows co-localization of the signal to the nuclei (blue). c, Automated analysis of a carcinoma with mixed P-catenin expression shows co-localization to both membrane (red), cytoplasmic (green) and nuclear (blue) compartments. Note that without subcellular localization, the overall expression of P-catenin in these three tumors would be similar. An additional confounding factor -the amount of surrounding desmoplastic stroma -is eliminated by using a mask (cytokeratin) that recognizes only tumor.
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Fig . 2 Step-by-step methodology for RESA and PLACE algorithms, a, Tumor cells are differentiated from stroma using a tumor-specific tag. Anti-cytokeratin is used to distinguish colon carcinoma from surrounding desmoplastic stroma. b, The cytokeratin image is gated to form a binary mask. c, The binary mask is enhanced by filling holes and removing small objects. d, An image of the membrane-specific tag is taken. Anti-acatenin is used to tag the membrane of a colon carcinoma. e, The membrane tag image is exponentially subtracted using RESA (Rapid Exponential Subtraction Algorithm). f, An image of the nucleus-specific tag is taken. DAPI is used to tag the nuclei of a colon carcinoma. g, The nuclear tag image is exponentially subtracted using RESA. h, The membrane and nuclear tag images are merged, and overlapping pixels are identified and removed. White pixels represent overlap. i, The membrane and nuclear compartments are overlaid on the tumor-specific mask. The overlay ensures that non-tumor nuclei and stroma are not included in the analysis of the target marker. j, An image of the targetspecific marker is taken, in this case, O-catenin expression of a colon carcinoma. k, The target marker image is exponentially subtracted using RESA. 1, The intensity of the marker is divided into the various subcellular compartments. In this tumor, 13-catenin is predominantly localized to the membrane (red) with minor amounts found in the nuclei (blue) and cytoplasm (green). Variables in boldface are statistically significant. *: Tumors with nuclear O-catenin levels in the top 10% were compared to the rest; t: tumors with nuclear/membrane P-catenin ratios in the top 25% were compared to the bottom 25%. Variables in boldface are statistically significant. *: Tumors with nuclear f0-catenin levels in the top 10% were compared to the rest; t: tumors with nuclear/membrane j3-catenin ratios in the top 25% were compared to the bottom 25%; t: 70% of tumors with high nuclear P3-catenin were node-positive versus 41% of tumors with lower levels. ABSTRACT HGF in breast cancers correlated with worse patient outcome (2, 3, 5) .
Whether HGF production by tumors and/or surrounding stroma is an Numerous studies have demonstrated that overexpression of Met, the important productic byatu mors and/or surroug tuor is an hepatocyte growth factor (HGF) receptor, plays an important role in important prognostic feature is unclear; although tumor cells themtumorigenesis. Met activation can either occur through ligand-indepenselves are a major producer of HGF (4, 5, 12) . The use of matriptase dent or -dependent mechanisms, both of which are mediated by a series of and HAI-I as prognostic markers in breast cancer has not been proteases and modulators. We studied the protein expression of several reported previously. However, recently, one study demonstrated that components of the HGF/Met pathway on a cohort of 330 node-negative high matriptase and low HAl-I levels were associated with advancedbreast carcinomas using a tissue microarray annotated with 30-year, stage ovarian tumors (13). Another report demonstrated that the disease-specific patient follow-up data. We examined HGF, matriptase (an glycosylation of matriptase stabilized and enhanced its proteolytic activator of HGF expressed on mammary epithelial cell surfaces). HAI-I activity, and promoted tumor aggression (14) .
(the cognate Inhibitor of matriptase), and the Met receptor itself. Our
The expression of Met has been more extensively studied. Met studies demonstrate tight correlation between the expression of HGF, overexpression associates with poor prognosis in a variety of tumors matriptase. and Met in breast carcinoma. High-level expression of Met, (1) . Whether such expression is ligand-(HGF) dependent or indematriptase, and HAI-I were associated with poor patient outcome. Met pendent is unclear; however, the constitutive activation of Met, via and HAl-I showed Independent prognostic value when compared with pendent is est abiv e T hese Metvi traditional breast markers in a multivariate analysis. Intriguingly, anti-several ligand-independent mechanisms, is established. These mechbodies against the Intracellular but not the extracellular domain of Met anisms include activating point mutations (15) (16) (17) (18) (19) , chromosomal were prognostic, suggesting that overexpression of the cytoplasmic-tail of translocations (20, 21) , and truncations of the cytoplasmic domain Met, perhaps through deavage or truncating mutation. may play an (22, 23) . In addition, dysregulation of Met-associated phosphatases important role in breast cancer progression.
may also lead to Met activation (24) . We have now studied several elements of the HGF pathway in -INTRODUCTION cluding HGF, matriptase, HAl-, and Met in a single cohort of node-negative breast cancer patients with 30-year follow-up, correMany studies have demonstrated the importance of the HGF 3 lating the expression of each element and determining their prognostic pathway in carcinogenesis (1) . HGF is produced both by tumor cells value. This study was facilitated by the use of tissue microarrays: as well as by surrounding stromal elements, and can act in either a arrays of hundreds of patient histological samples on a single glass paracrine or autocrine fashion (2) (3) (4) (5) . HGF is secreted as an inactive slide. Our study demonstrates a significant correlation between mempropeptide, which must be cleaved to become biologically active. One bers of the HGF pathway and shows that several members have enzyme responsible for this cleavage is matriptase, an epithelial-independent prognostic value in determining patient outcome. localized transmembrane serine protease (6-8). Matriptase is, in turn, regulated by a naturally occurring inhibitor, HAl-I (9, 10). When MATERIALS AND METHODS cleaved, HGF can bind to its receptor, Met, thereby stimulating cleaedHOFcan indto ts eceporMet threbystiulaing Cohort Design and Tissue Microarray Construction. Tissue microarrays m ultiple dow nstream pa thw ays, leading to m itogenesis, m otogenes is, C o o tD s g an l s e Mi r r ay o s ru t n.T s e mi o ra s andmultipldowogenesis ( . were constructed, as described previously, and reviewed recently (25, 26) . and morphogenesis (11).
Three hundred and thirty cases of formalin-fixed, paraffin-embedded, nodeSeveral studies have analyzed individual components of the HGF negative breast carcinoma were obtained from the archives of the Department pathway for their association with tumor aggression and/or patient of Pathology, Yale University. Cases were taken sequentially, as available, survival. Early biochemical studies demonstrated that overall levels of from 1962 to 1980, with a median survival time of 15.6 years. Complete treatment history is not available from this cohort, but the vast majority of Received 8/28/02; accepted 1/3/031 patients in this era were not treated with chemotherapy. Representative tumor
The costs of publication of this article were defrayed in part by the payment of page regions were selected for coring by a pathologist (R. L. C.). Because prior charges. This article must therefore be hereby marked advertisement in accordance with studies have demonstrated that a single core adequately represents the staining 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by grants from the Patrick and Catherine Weldon Donaghue Foundation pattem of an entire slide, all of the studies were performed using a single for Medical Research, The Connecticut Breast Cancer Alliance, and grants from the NIH, sample of each tumor (27, 28) . Our previous study has also demonstrated the including National Institute of Environmental Health Sciences Grant KO-8 ES 11571 (to durability of antigens from archival specimens as old as 70 years (27) . In the R. L. C.), National Cancer Institute Grant RO-1 GM57604 (to D. L. R.), United States present study, all of the tumors demonstrated some degree of staining with one Army Grant DAMD 01-000436. and NTH Breast Cancer Specialized Programs of Reor more of the antibodies tested. denonstratin that no -ases were antigenc II search Excellence 2P50CA72460. g h a giay 2 To whom requests for reprints should be addressed, at Department of Pathology, Yale "dead" because of fixation artifacts or tissue age. University, School of Medicine, 310 Cedar Street, BML 122. New Haven, Ct 06520.
Immunohistochemistry. Briefly. 5-gzm tissue microarray slides were E-mail: robert.camp@yale.edu.
deparaffinized with xylene and ethanol. Antigen retrieval was performed using 3 The abbreviations used are: HGF. hepatocyte growth factor; HAI, hepatocyte growth citrate buffer (pH 6.0) pressure-cooking (29) . Primary antibodies were incufactor activator inhibitor; ER, estrogen receptor; PR, progesterone receptor: CI, confidence interval; uPA, urokinase-type plasminogen activator; PAl. plasminogen activator bated overnight at 4°C, with the exception of antibodies to ERs, PRs, and Her2, inhibitor, which were incubated at room temperature for I h. Monoclonal anti-matriptase
MET. MATRIPTASE. HAM, AND NODE-NEGATIVE BREAST CANCER
and anti-HAl-I antibodies were prepared as described previously (9. 30). ent observers (J. Y. K. and M. D-F.), and histocores with discrepant scores Commercially acquired antibodies included: polyclonal (goat) anti-HGF anti-were re-examined by both observers to achieve a consensus score. Cases with body (R&D Systems, Minneapolis, MN); monoclonal antibody to the extra-scores of 2+ or 3+ were designated as "high." whereas cases with scores of cellular domain of Met (DO-24; Upstate Biotechnology, Lake Placid, NY); and 0 or I + were designated as "low.*" monoclonal antibody to the intracellular domain of Met (3D4; Zymed, South Statistical Analysis. All of the analyses were completed using Statview San Francisco, CA). The specificities of all of the antibodies used were verified 5.0.1 (SAS Institute Inc., Cary, NC). Correlations between markers were using immunoprecipitation and Western blotting. Antibodies to ER, PR, and performed using a X2 test. Prognostic significance was assessed using both IIER-2/neu were obtained from DAKO (Carpinteria, CA) and used according univariate and multivariate Cox proportional hazards models with 30-year to the manufacturer's specifications. Antibodies were either detected using a survival as an end point. Survival curves were calculated using the KaplanVectastain ABC kit (Vector Laboratories, Burlingame, CA) for anti-HAl-I or Meier method, with significance evaluated using the Manel-Cox log rank test. the DAKO Envision TM + System (DAKO) for the others. Signal from the HGF antibody was amplified using biotin-tyramide signal amplification fol-RESULTS lowed by a streptavidin-horseradish peroxidase conjugate (TSA kit; PerkinElmer Life Sciences, Boston, MA). Staining was visualized using diaminoWe analyzed the expression of several components of the Met benzidine and counterstained with acidified hematoxylin. Slides were also pathway including HGF, matriptase, HAl-l, and Met itself (using both stained in the absence of primary antibody to evaluate nonspecific secondary intracellular-and extracellular-specific antibodies; Fig. 1) . The numantibody reactions.
ber of tumors expressing high levels of these antigens ranged from 18 Evaluation of Immunostaining. Immunostaining was scored on a scale Of to 46% ( Table 1) . Although tissue microarrays have been shown to 0 to 3+ (negative/weak/moderate/intense staining). Distinctions between membrane and cytoplasmic staining were impractical given the diffuse staining adequately represent tumor antigen expression (27) , they most likely of the antigens (visualized using the chromogenic substrate, diaminobenzido not fully represent the expression of stromal markers. Therefore, dine). Therefore, scores represent the combined staining intensity of membrawe limited our analysis to the expression of markers by tumor cells nous and cytoplasmic staining. Histospots with < 10% of their area covered by and not stroma. In the case of HGF, this resulted in our selective study tumor were excluded from analysis. Scoring was performed by two independof autocrine (tumor) expression. at low (X40) and high (X200, insels) magnification. Matriptase, HAl-t. and Met show6 a membrano-cytoptasmic localization, whereas HOF is predominantly cytoplasmic. The cellular tocalzation of Met using antibodies to the intracellular and extraceflular domains was comparable (D, left and right insets, respectively). Representative histospots stained using an antibody to the intracellular domain of Met and scored as 0, 1. 2, or 3+ are shown in E-Hl respectively. "The association among expression of matriptase, HGF, HAl-l, and Met (usm components. Using multivariate analysis, both the cytoplasmic tail of antibodies to both the cytoplasmic and extracellular domains) were determined using xk Met and HAl-I retained independent predictive power ( Table 4 ).
MET, MATRIPTASE, HA-I.I AND NODE-NEGATIVE BREAST CANCER
analysis. Statistically significant observations are in boldface. All significant associations When we included these two markers with traditional breast cancer are direct (i.e. high-expression of one marker correlates with high-expression of the other), markers, they retained their independence. Tumor size was the only other independent predictor of poor outcome (Table 5) . To elucidate potential associations between these markers, we .2 performed X2 analyses, which revealed highly significant associations 0 p=0.0267 p-0.0098 between the expression of Met, HGF, and matriptase (P < 0.0002;
. 1 1... ... ..... . Table 2 ). HAl-I expression was independent of these markers, al-.8GF Survival lim (months) though it trended toward coexpression with matriptase (P = 0.0597).
.8
Interestingly, the expression of antibodies to the intracellular and .8. extracellular domains of Met were highly correlated (P < 0.0001; A -Low expression Table 2 ), but not coincident; 38 cases were scored as entirely Meta -i extracellular negative (score of 0) and Met-intracellular high (12.2%), 0 p=0.5021 whereas only I case was judged as entirely Met-intracellular negative 2 1051 and Met-extracellular high (0.3%). This result suggests that relative Survival Time (months) overexpression of the intracellular domain of Met is far more common Fig. 2 . Kaplan-Meier analysis of disease-related survival demonstrates that Met (inthan relative overexpression of the extracellular domain. tracellular domain), matriptase, and HAl-1 show long-term prognostic benefit. Statistical To determine the predictive power of the Met pathway, we initially significance was assessed using the log rank test. performed a univariate analysis of individual Met pathway components and compared them with traditional breast cancer markers (Table 3) . Table 4 Multivariate analysis: Met pathway' Because breast carcinoma can recur and kill patients decades after its ini tial d iag n o sis, w e stud ied 30 -y ear disease-re la ted su rv iva l. U sing u n i-M e t--cytopla s ic) P portion, showed prognostic power (P = 0.0029; "" Multivariate analysis of 3 0-year disease-related survival was performed using the High-level matriptase expression was also predictive of Loor outcome
Cox-proportional hazards model using only the experimental markers. Statistically sig-(51% dead of disease versus 40%; P = 0.0279; domain. Third, high levels of the cytoplasmic tail of Met were
Multivariate analysis of 30-year disease-related survival was performed using the predictive of poor outcome, whereas expression of the extracellular
Cox-proportional hazards model using both the independent markers from Table 4 and portion was not. Although this result could be explained by differtraditional histopathologic measures. Statistically significant observations are in boldface.
ences in the affinity of the antibodies for Met in formalin-fixed, paraffin-embedded tissue, both antibodies gave strong staining and DISCUSSION similar results across a range of titrations (data not shown). A more likely explanation is that the cytoplasmic tail of Met is either cleaved The relative importance of ligand-dependent and ligand-indepen-(e.g.. after activation) or that mutations in Met lead to an overexpresdent Met activation in carcinogenesis is a matter of continued debate sion of the cytoplasmnic tail in some tumors. Indeed, recent studies (1). Our studies demonstrate that members of the HGF pathway, have suggested that the cleavage of the cytoplasmic tail of Met may namely HGF, Met, and matriptase, are often coexpressed on breast be important in signal transduction (1, 22, 23) . Whether overexprescancers, and that high-level expression of two of these members, Met sion of the Met intracellular domain relative to the extracellular and niatriptase, associates with more aggressive tumors. Such obser-domain is a ligand-independent or -dependent phenomenon is unclear. vations would be expected if HGF-mediated Met stimulation played a Interestingly, expression of the Met extracellular domain correlates role in tumorigenesis. Although tumoral HGF levels were not found to with HGF levels but not matriptase levels, whereas the Met intracelbe predictive of outcome, the expression of matriptase was prognostic lular domain correlates with both. This observation would be expected in a univariate analysis, suggesting that as an activator of HGF, it if the binding of matriptase-potentiated HGF to Met induced a subplays a rate-dependent ("gate-keeping") role in the ligand-dependent sequent cleavage of the Met intracellular domain. stimulation of Met.
In summary, we have made use of tissue microarray technology to In addition to their role in the activation of HGF, matriptase and its analyze various components of the Met-signaling pathway. Our studcognate inhibitor, HAl-1, also play a role in the plasminogen activator ies provide evidence that the expression of the stimulatory members cascade (6, 31, 32) . This cascade culminates in the activation of of this pathway (Met, HGF, and matriptase) is tightly correlated. plasmin and the coactivation of matrix metalloproteinases, both of High-level HAl-I expression is an independent predictor of outcome. which degrade extracellular matrix components and potentiate tumor Furthermore, studies using antibodies to different domains of the Met cell invasion, extravasation, and metastasis (33) . Matriptase promotes receptor suggest that overexpression of the cytoplasmic domain is a this pathway by activating latent uPA, which, ;n turn, activates plas-strong independent predictor of outcome. min (6, 34) . Like matriptase, uPA can also cleave pro-HGF, providing another level of interaction between the Met/HGF pathway and plasmin cascade (35) . Given the multiple functions of matriptase, it is not ACKNOWLEDGMENTS surprising that aggressive breast tumors produce higher levels of this We thank Thomas D'Aquila and Lor Charette for their help in this effort. enzyme.
Likewise, HAl-I, as an inhibitor of matriptase, may help modulate both the Met/HGF and plasmin pathways. Interestingly, the expres-REFERENCES sion of HAl-I was independent of the other members of the Met
The single best indicator of disease free survival and breast carcinoma with an emphasis on the correlation overall survival in patients with breast carcinoma between the markers. We studied expression patterns is lymph node status.' Patients who have breast carof Met, EGFR, fibroblast growth factor receptor cinomas with axillary lymph node metastases have a (FGFR), and HER-2/neu on a cohort of patients with 10-year recurrence rate approaching 70%.2 However, long-term follow-up. in patients with lymph node negative breast carcinoma, there are no markers used to predict outcome MATERIALS AND METHODS that consistently show statistical significance. In this Tissue Microarra Construction group, predicting a worse outcome is of great impor-
The tissue microarrays were constructed as described tance, because as many as 20% of women with lymph previously' 6 and as reviewed recently." 4 Briefly, fornode negative breast carcinoma eventually will die of malin fixed, paraffin embedded tissue blocks containmetastatic disease. 3 Numerous prognostic markers ing breast carcinoma specimens were retrieved from have been tested to try to predict outcome in this the archives of the Yale University Department of Pagroup. In large studies with long follow-up, the best thology. Areas of invasive carcinoma were identified predictors of outcome were tumor size, tumor grade, on corresponding hematoxylin and cosin-stained cathepsin-D expression, Ki-67 expression, S-phase slides, and the tissue blocks were cored and transfraction, mitotic index, and vascular invasion. Howferred to a recipient master block using a Tissue Miever, despite their marginal statistical status, tumor croarrayer (Beecher Instruments, Sun Prairie, WI). size and tumor grade enjoy broad acceptance as progEach core measured 0.6 mm in greatest dimension, nostic factors this group of patients. 4 and cores were spaced 0.8 mm apart. After cutting the "Tyrosine kinase receptors (RTKs) are gaining atrecipient block and transfer with an adhesive tape to tention as prognostic markers and as possible future coated slides for subsequent ultraviolet cross linkage predictive markers as the number of trials grows for (Instrumedics, Inc., Htackensack, NJ), the slides were biospecific inhibitors. Among these, HER-2 (erb B2 dipped in a layer of paraffin to prevent oxidation. The and neu), epidermal growth factor receptor (EGFR), array for the cohort of patients with lymph node negand Met (c-met) have been documented as prognosative breast carcinoma was constructed from paraffin tically significant markers for invasive breast carcinoembedded, formalin fixed tissue blocks from the Yale mas predicting a worse prognosis. HIER-2 has been University Department of Pathology archives. The associated with outcome in patients with lymph node specimens were resected between 1962 and 1980, with positive tumors but has not proven valuable in paa follow-up that ranged between 4 months and 53.8 tients with lymph node negative tumors.
5 Although years, with a mean follow-up of 15.6 years and a mesome studies have suggested that EGFR is valuable,' dian follow-up of 14.3 years. EGFR has been examined in over 25 studies, of which only approximately 50% suggest that overexpression is associated with poor outcome.
7 Met has also shown Grading mixed results. Although we and others have found Met Nuclear grade was evaluated by one observer (H.T.O.) useful in predicting worse outcome, 8 -t others either according to the methods described by Fisher et al."" have not seen the correlation or have found an oppoon each spot. Due to the age of the specimens, they site correlation." Finally, FGFR has been studied less were not assigned a nuclear grade previously. Presand has shown no definitive prognostic value for paence or absence of necrosis, mitotic count, or histotients with breast carcinoma.' 2 logic parameters could not be included in the grading Slide-to-slide standardization is a long-standing criteria because of the small size of the area evaluated. problem in immunohistochemistry studies and may Eighty of 306 included specimens (26%) were Grade 1, be one explanation for the variability seen in the stud-170 specimens (56%) were Grade 2, and 56 specimens ies described earlier. Tissue microarray technology (18%) were Grade 3. Similar to previous studies of can eliminate this problem.'t' 4 Tissue microarrays are nuclear grade in lymph node negative tumors, no staa method of placing very small samples of tissue from tistical significance was achieved. However, a trend hundreds or thousands of patients on a single was seen between high nuclear grade and worse outslide.'•" 6 The technology has been used extensively come (5-year survival).
and is the subject of multiple reviews. 14, 17, 11 hydrogen peroxide/ methanol buffer. Antigen retrieval F a dption ordinal scoring of expression and the selection of cut-off values to deie positive was performed by boiling the slides in a pressure staining for sch mar•. see test. cooker filled with a sodium citrate buffer, pH 6.0. After antigen retrieval, the slides were incubated with 0.3% bovine serum albumin/I X Tris-buffered saline (TBS) cytoplasmic domains) were determined separately for for I hour at room temperature to reduce nonspecific each specimen. The staining intensity was graded on background staining, followed by a series of 2-minute the following scale: 0, no staining; 1, weak staining; 2, rinses in 1 X TBS, TBS/0.01% Triton, and 1 X TBS. moderate staining; and 3, intense staining. The memPrimary antibody was applied for 1 hour at room branous staining was determined for HER-2 and temperature. Dilutions for the RTKs were as follows:
EGFR. The staining intensity for membranous staining Met, 1:1 (note that this antibody was provided as a was graded on the following scale: 0, no staining; 1, culture supernate from Zymed Laboratories, Inc., incomplete staining; 2, weak but complete staining of South San Francisco, AC); EGFR, 1:200; FGFR, 1:300;  the plasma membrane encircling the entire cell; and 3, and HER-2, 1:8000. After a series of TBS rinses, as intense complete staining. Again, we did not take the described above, bound antibody was detected by uspercentage of cells with staining in consideration being an antirabbit, horseradish peroxidase-labeled, cause of the small size of the tumor sections. For polymer secondary antibody from the DAKO Envision specimens that were uninterpretable, a score of not TM + System (DAKO, Carpinteria, CA). The slides available was given. Only FGFR showed distinctly sepwere rinsed in the TBS series and visualized with a arate nuclear and cytoplasmic staining characteristics; 10-minute incubation of liquid 3,3'-diaminobenzidine and, for this antibody, nuclear staining and cytoplasin buffered substrate (DAKO) for 10 minutes. Finally, mic staining were scored individually. Scoring of the the slides were counterstained with hematoxylin and tissue microarrays was completed by two independent mounted with Immunomount (Shandon, Pittsburgh, observers (I.T.O and M.D.F.) for EGFR, FGFR nuclear PA). Immunohistochemical staining also was done for staining, FGFR cytoplasmic staining, and Met with a estrogen receptor (ER), progesterone receptor (PR), very high correlation between scorers (P < 0.0001). and HER-2, as described previously. M.D.F.). Ki-67 was considered positive if > 10% of was provided as part of a collaborative arrangement nuclei were stained. Frequency distributions for these with Zymed Laboratories, Inc.; the EGFR antibody was markers were in the range of other works seen in the EGFR 1005 (catalog no. SC03) from Santa Cruz Bioliterature, validating this cohort (see Table 1 ). technology, Inc. (Santa Cruz, CA); and the FGFRI antibody was FLC CI5 (catalog no. SC121; Santa Cruz Statistcal Analysis Biotechnology, Inc.).
All analyses were completed using Statview software (version 5.0.1; SAS Institute Inc., Cary, NC). The corEvaluation of Inununohistochemical Staining relation between the scores of both scorers and the For each spot, the regions of most intense and/or relations among the different immunohistochemical predominant staining pattern were scored by eye. Traand clinicopathologic parameters were measured usditionally, immunohistochemistry scoring of stain ining the chi-square test. The prognostic significance of tensity includes a variable for the area percentage parameters on overall survival was calculated by mulstained with the specimen; however, due to the small tivariate analysis using a Cox proportional hazards size of the spot (0.6 mm in greatest dimension) and model. Survival curves were calculated using the the fact that the spots often are homogenous, no area Kaplan-Meier survival analysis method with the difvariable was included. Nuclear staining and/or cytoferences estimated using the Mantel-Cox log-rank plasmic staining (ER/PR, EGFR, FGFR, Ki-67, and Met test. 
RESULTS
sial. In this study, we tried to use breakpoints sug-"The RTKs analyzed in this study showed a variety of gested previously in the literature when they were staining patterns that are summarized in Figure 1 . present"'°; however, in some instances (FGFR), there Although all RTKs are present at the membrane, there
were not clear precedents in the literature or the litare now numerous studies showing that RTKs can be erature was inconsistent (EGFR). A summary of the found in other locations in the cell, including both the expression pattern of each RTK is shown in Table 2 cytoplasm and, more recently, the nucleus.
2 ' The patwith the definition of the cut-off values. terns we saw included both conventional membraIn this study, we were concerned primarily with nous patterns as well as both cytoplasmic and nuclear the correlation between each RTK and the correlation staining (for a detailed description, see above). The of each RTK with known prognostic markers. We calpattern of expression of each RTK was determined culated chi-square P values to determine the correlaafter examining the entire array to determine the most tion among expression patterns of individual paramprevalent patterns. The question of how to divide subeters. Table 3 shows the chi-square P values for all jective ordinal staining patterns always is controverparameters studied in patients with lymph node neg- Cox univariate analyses at 10 years for all variables pothesis that HER-2 is not a reliable prognostic studied in patients with lymph node negative breast marker in this group of patients. carcinoma are shown in Table 4 . Ki-67 and tumor sie, EGFR expression in breast carcinomas has been as expected, were correlated with poorer survival (Kireported, both in patients with lymph node negative 67: P = 0.04; relative risk [RR], 1.648; tumor size: P breast carcinoma and in patients with lymph node = 0.0008; RR, 2.201). Among the other variables studpositive breast carcinoma, as associated with poor ied, only the cytoplasmic domain of Met showed a prognosis; however, the clinical significance and assostatistically significant correlation with a worse progciation with disease free survival (DFS) and overall nosis and shortened survival (P = 0.0035; RR, 2.041).
survival statistics show mixed results in different studSurvival curves were produced for each variable, but ies. 3 8 -4 0 Tsutsui et al. reported that EGFR carries a only Met reached statistical significance using the prognostic significance only for DFS in patients with Mantel-Cox log-rank test (Fig. 2) . To determine the lymph node negative tumors on multivariate analysis; independent predictive value of Met expression, a whereas, in the series by Torregrosa et al., EGFR failed multivariate analysis was conducted using the Cox to show statistical significance as a prognostic marker proportional hazards model. In multivariate analysis, in patients with lymph node negative tumors but was Met retained its significance as a predictor of worse associated with a worse prognosis, influencing DFS in outcome, even when the model contained all of the patients with lymph node positive tumors. Conversely, conventional prognostic variables as well as all other Seshadri et al. concluded that the expression of EGFR RTKs tested (R1, 1.86; P = 0.011).
was not at all a predictor of poor prognosis in patients with lymph node negative breast carcinoma. Our find-
DISCUSSION
ings did not show any value for EGFR as a marker of In patients with lymph node negative breast carciprognosis in patients with lymph node negative tunoma, we still are unable to discern the 15-20% of mors. patients who eventually will succumb to their disOur group has been particularly interested in the ease.' 2 2 A long list of potential molecular markers of hepatocyte growth factor receptor, Met (or C-met). poorer prognosis have been suggested for this group Met is a dimeric tyrosine kinase growth factor receptor patients with breast carcinoma, including Ki-67, 23 2 4 in which activation is associated with increased invacathepsin-D, Our previous studies showed that expression of C-terminus. In another study from our laboratory, 43 the Met receptor in patients with invasive breast carwe compared the results from this antibody with ancinoma is of significant prognostic value in determinother monoclonal antibody to the extracellular doing patient survival, even in patients with negative main of Met. We showed results with the cytoplasmic lymph nodes.
8 9' The Vande Woude group also found domain similar to the results reported here, but the this correlation between Met expression and outextracellular domain was very different. Although come;`0 although, along with others, we found no there is a high correlation of expression, overexprescorrelation in some cohorts (unpublished data). We sion, as assessed by the antibody to the cytoplasmic believe this variability is due to antibody selection, domain, selects a group of patients with worse outMany studies have used antibodies to the c-terminal come, whereas the extracellular domain antibody domain produced by Santa Cruz Biotechnology, Inc., does not. 43 We believe this may be a function of either using a peptide coding for the C-terminal 28 amino cleavage or activation of Met. It is notable that the acids. We found significant lot-to-lot variability with other study that found a correlation between Met exthis antibody. Recently, Zymed laboratories, Inc. and pression and patient outcome also used a monoclonal others have produced monoclonal antibodies to the antibody (generated by the Vande Woude laborato- Validation of Microarray Cohort. To validate our tissue microarpression levels were greater than the mean HER2 expression on ray cohort of 300 node-positive breast cancers, we assessed several normal epithelium + I SD (AQUA score <6.5; Fig. 1 , A and C. On traditional histopathological markers of malignancy. Using univariate the basis of these divisions, 17.5% of the tumors were designated analysis of long-term disease-related survival, we found that large HER2 normal, 71.3% were HER2 intermediate, and 11.2% were tumor size, high nuclear grade, low estrogen receptor expression, and HER2 high. high number of involved lymph nodes were all significant predictors
Comparison of Manual and Automated Techniques. We then of poor outcome ( Table 1) . We next assessed the prognostic power of compared HER2 expression as gauged by automated and manual HER2 immunohistochemistry, using standard brown staining, visual techniques ( Fig. 1, panels C and B, respectively) . In contrast to examination by a pathologist, and scoring on a four-point scale (0 to AQUA scores, which were continuously scored on a scale of 0-255, 3+). Manual analysis showed a typical pattern of HER2 expression manual scoring of HER2 expression was performed on a nominal with 15% of tumors overexpressing the antigen (2+ and 3+; Fig. IB) .
four-point scale (0 to 3 +). Despite this difference, regression analysis As expected, high-level (3+) tumors showed a significantly worse demonstrated good correlation between the two methods (r = 0.704). outcome with a relative risk of 2.25 (P = 0.0007; Table 1 ). Analysis However, there was a significant degree of overlap in the automated of HER2 gene amplification by FISH was not predictive in our study, scores of cases from adjacent manually determined groups (Fig. ID) . but this was most likely attributable to the relatively small number of Whereas there was a clear division between the histograms of tumors cases that, for technical reasons, were scorable (125 of 300; Table 1 ).
scoring 0/1 + and 2+/3+, the distinction between tumors scoring 0 However, both automated and manual analyses of HER2 protein and I + was indistinct. This result shows the difficulty in manually levels were highly correlated with HER2 gene amplification translating a biological (continuous) marker into a nominal four-point (P < 0.0001). The percentage of HER2-amplified cases in each scale. Even for the trained eye of a pathologist, accurate distinction manual category were 4.0% (0), 13.7% (1+), 71.4% (2+), and 75.0% between nominal categories (e.g., 2 + versus 3 +) is difficult and often (3+), and in each AQUA category were 9.5% (normal), 13.7% arbitrary. Indeed, recent studies have demonstrated a significant lack (intermediate), and 77.8% (high).
of reproducibility in the clinical determination of HER2 levels attrib-HER2 Expression on Normal Epithelium. We then assessed the utable in part to this difficulty (7-9). level of HER2 expression on normal breast epithelium with use of Examination of manual and automated techniques revealed that both were equally able to define a population of tumors expressing 
